Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 4:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 2,795 matching trials from the live ClinicalTrials.gov search.
Conditions
Tetanus, Diphtheria, Pertussis, Measles, Polio
Interventions
Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus, Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
3,372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
71
States / cities
Birmingham, Alabama • Pinson, Alabama • Trussville, Alabama + 60 more
Conditions
Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia
Interventions
Asparaginase, Biospecimen Collection, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Lestaurtinib, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Pegaspargase, Pharmacological Study, Prednisone, Therapeutic Hydrocortisone, Vincristine Sulfate
Drug · Procedure · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 1 Year
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
157
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 120 more
Conditions
Chronic Hepatitis C
Interventions
Taribavirin, Ribavirin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Terminated Phase 4 Interventional Results available

Aspirin and Enoxaparin for VTE in Trauma

NCT02396732
Conditions
Venous Thromboembolism, Thromboprophylaxis, Trauma
Interventions
Aspirin, Enoxaparin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Lenalidomide, Acetaminophen, Diphenhydramine, Montelukast, Carfilzomib, Daratumumab, Autologous Stem Cell Transplant (ASCT)
Drug · Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Miami, Florida • Tampa, Florida • Buffalo, New York + 4 more
Conditions
Glioblastoma, Recurrent Glioblastoma
Interventions
ASP8374, cemiplimab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 1 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Daily Report Card, Language Intervention
Behavioral · Other
Lead sponsor
Florida International University
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Conditions
Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine, HZ/su vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
11
States / cities
Daphne, Alabama • Tempe, Arizona • Corte Madera, California + 8 more
Conditions
Leukemia
Interventions
MEK-162, Nilotinib, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma
Interventions
Lenvatinib, Pembrolizumab, Hypofractionated External Beam Radiation Therapy, High-Dose Rate (HDR) Brachytherapy
Drug · Radiation
Lead sponsor
Aaron Wolfson
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1
States / cities
Miami, Florida
Conditions
Anxiety, Depression, Suicide
Interventions
Psychoeducation and Cognitive Bias Modification
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Tallahassee, Florida
Conditions
Chronic Lymphocytic Leukemia, Richter's Transformation
Interventions
Glofitamab, Obinutuzumab, Polatuzumab Vedotin, Atezolizumab, Tocilizumab, Pirtobrutinib
Drug
Lead sponsor
Christine Ryan
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam

NCT03978091
Conditions
Bacterial Infection
Interventions
AZACTAM, Ceftazidime-Avibactam
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Chlamydia, Gonorrhea, HIV
Interventions
HIV testing, STI/HIV-T, STI/HIV-Plus
Behavioral
Lead sponsor
North Bronx Healthcare Network
Other
Eligibility
14 Years to 21 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Exudative Age-Related Macular Degeneration
Interventions
ranibizumab and dexamethasone, Ranibizumab
Drug
Lead sponsor
Subhransu K. Ray, M.D., Ph.D.
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Walnut Creek, California
Terminated Not applicable Interventional Accepts healthy volunteers

Parent Intervention to Reduce College Student Drinking and Consequences

NCT04247191
Conditions
Underage Drinking, Driving Under the Influence, Drinking, Teen, Drinking, College
Interventions
P-Chat+, PBI
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 19 Years
Enrollment
2,061 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
University Park, Pennsylvania
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Untreated Adult Acute Myeloid Leukemia
Interventions
cytarabine, daunorubicin hydrochloride, etoposide, valspodar
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Brain Injury
Interventions
Polypharmacy using FDA-approved products, Median Nerve Stimulation (MNS), Nutraceutical Supplementation, Standard of Care
Drug · Device · Dietary Supplement + 1 more
Lead sponsor
International Brain Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Edison, New Jersey
Conditions
Diabetes Mellitus, Type 1
Interventions
Hybrid Closed Loop Insulin Pump System
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Santa Monica, California • Sylmar, California • Torrance, California
Conditions
Obesity
Interventions
Placebo, IHBG-10
Other · Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Not yet recruiting Phase 3 Interventional

ITM vs ITM+Clonidine for Lumbar Fusions

NCT07846657
Conditions
Lumbar Fusion Surgery
Interventions
Intrathecal Morphine + Intrathecal Clonidine, Intrathecal Morphine
Drug
Lead sponsor
MaineHealth
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Maine
Conditions
Stroke, Hemiplegia, Cerebrovascular Accident (CVA), Hemiparesis
Interventions
Contralaterally Controlled Functional Electrical Stimulation, New rTMS approach, Conventional rTMS approach, Sham rTMS approach
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Recurrent Glioblastoma
Interventions
Cediranib, Lomustine Chemotherapy, Placebo Cediranib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Pheonix, Arizona • Los Angeles, California + 18 more
Completed Phase 4 Interventional Results available

SISTERS: Spasticity In Stroke Study - Randomized Study

NCT01032239
Conditions
Severe Spasticity
Interventions
intrathecal baclofen
Drug
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
9
States / cities
Irvine, California • Washington D.C., District of Columbia • Doral, Florida + 6 more